HRP20150096T1 - 2-aminobenzimidazol-5-karboksamidi kao protuupalni agensi - Google Patents

2-aminobenzimidazol-5-karboksamidi kao protuupalni agensi Download PDF

Info

Publication number
HRP20150096T1
HRP20150096T1 HRP20150096AT HRP20150096T HRP20150096T1 HR P20150096 T1 HRP20150096 T1 HR P20150096T1 HR P20150096A T HRP20150096A T HR P20150096AT HR P20150096 T HRP20150096 T HR P20150096T HR P20150096 T1 HRP20150096 T1 HR P20150096T1
Authority
HR
Croatia
Prior art keywords
alkyl
groups
optionally substituted
fluoro
last
Prior art date
Application number
HRP20150096AT
Other languages
English (en)
Inventor
Roland Pfau
Kirsten Arndt
Henri Doods
Klaus Klinder
Raimund Kuelzer
Dimitrijs Lubriks
Juergen Mack
Benjamin Pelcman
Henning Priepke
Robert Roenn
Dirk Stenkamp
Edgars Suna
Original Assignee
Orexo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42111729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20150096(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orexo Ab filed Critical Orexo Ab
Publication of HRP20150096T1 publication Critical patent/HRP20150096T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (19)

1. Spojevi opće formule I [image] jedan od X i Y predstavlja -N(R6)-; i drugi predstavlja -N= ; jedan od Z1, Z2 i Z3 neovisno predstavlja -C(R7)= ili -N=; i druga dva od Z1, Z2 i Z3 predstavljaju -C(R7)=; Q2, Q3 i Q4 predstavljaju odgovarajući -C(R2)=, -C(R3)= i -C(R4)=; ili bilo koji ili bilo koja dva od Q2, Q3 ili Q4 mogu naizmjence i neovisno predstavljati -N=; R1 predstavlja halo, OH, -CN; C1-3 alkil, C2-6 alkinil, OC1-3 alkil, gdje su zadnje tri skupine opcionalno supstituirane s jednim ili više supstituenata odabranih od fluoro, -CN, =O, OH, -OCH3, -OCF3; R2, R3 i R4 neovisno predstavljaju vodik, halo, -CN; C1-3 alkil, OC1-3 alkil, gdje su zadnje dvije skupine opcionalno supstituirane s jednim ili više supstituenata odabranih od fluoro, -CN, =O, OH, -OCH3, -OCF3; Ra, Rb neovisno predstavljaju vodik, C1-3 alkil, ili oba zajedno s ugljikovim atomom na koji su vezani, čine C3-7 cikloalkilenski prsten, ili 4-6-člani heterocikloalkilenski prsten; Rc predstavlja vodik ili C1-3 alkil; W predstavlja -C(O)-, -S(O)-, -S(O)2-, -C(O)O-, ili -C(O)NRd-, gdje su skupine vezane za dušik iz -NRc- dijela preko atoma ugljika ili sumpora; Rd predstavlja vodik ili C1-3 alkil; M predstavlja C1-7 alkil, C3-7 cikloalkil, gdje su obje skupine opcionalno supstituirane s jednom ili više skupina odabranih od fluoro, -OH, -CN, -NH2, -NH(C1-3 alkil), N(C1-3 alkil)2, -OC1-3 alkil, -SC1-3 alkil, aril, heteroaril [gdje dvije zadnje skupine mogu biti supstituirane s jednim ili više supstituenata odabranih od halo, OH, -CN, C1-3 alkil, OC1-3 alkil (gdje su zadnje dvije alkilne skupine opcionalno supstituirane s jednim ili više atoma fluora)], C1-7 alkil, C2-7, alkinil, C3-7 cikloalkil-C0-2alkil, 4-7-člani heterocikloalkil-C0-2 alkil (gdje su zadnje alkil, alkinil, heterocikloalkil ili cikloalkil skupine opcionalno supstituirane s jednim ili više supstituenata odabranih od fluoro, -CN, =O, -NH2, -NH(C1-3 alkil), -N(C1-3 alkil)2, -OH, -OC1-3 alkil); ili aril, heteroaril, 4-7-člani heterocikloalkil, od kojih su sve skupine opcionalno supstituirane s jednim ili više supstituenata odabranih od halo, -OH, -CN, -NH2, -NH(C1-3 alkil), -N(C1-3 alkil)2, -OC1-3 alkil, -SC1-3 alkil, aril, heteroaril [gdje zadnje dvije skupine mogu biti supstituirane s jednim ili više supstituenata odabranih od halo, OH, -CN, C1-3 alkil, -OC1-3 alkil (gdje su dvije zadnje alkilne skupine opcionalno supstituirane s jednim ili više atoma fluora)], C1-7 alkil, C2-7 alkinil, C3-7 cikloalkil, 4-7-člani heterocikloalkil (gdje su zadnje alkil, alkinil, heterocikloalkil ili cikloalkil skupine opcionalno supstituirane s jednim ili više supstituenata odabranih od fluoro, -CN, =O, -NH2, -NH(C1-3 alkil), N(C1-3 alkil)2, -OH, -OC1-3alkil)]; R5 predstavlja vodik; ili C1-3 alkil; R6 predstavlja vodik; C1-5 alkil, C3-6 alkinil, 4-7-člani heterocikloalkil-C0-2 alkil ili C3-7cikloalkil-C0-2 alkil (gdje su zadnje četiri skupine opcionalno supstituirane s jednim ili više supstituenata odabranih od fluoro, -CN, =O, C1-3 alkil, -OH, -OC1-3 alkil, -NH2, -NH(C1-3 alkil), N(C1-3 alkil)2); svaki R7 neovisno predstavlja vodik, halo, -CN, C1-7 alkil, C2-7 alkinil, C3-7 cikloalkil, C1-5 alkil-O-, C3-7cikloalkil-C0-2 alkil-O-, 4-7-člani heterocikloalkil-C0-2 alkil-O-, (gdje je zadnjih šest skupina alkil, alkinil, cikloalkil ili heterocikloalkil fragmenata opcionalno supstituirano s jednim ili više supstituenata odabranih od fluoro, -CN, =O, OH, -OC1-3 alkil, -NH2, -NH-C1-3 alkil, N(C1-3 alkil)2 ili s jednim ili više C1-3 alkil skupina, koje mogu biti opcionalno supstituirane s jednim ili više atoma fluora); ili aril ili heteroaril, gdje zadnje dvije skupine mogu biti supstituirane s jednim ili više supstituenata odabranih od halo, OH, -CN, C1-3 alkil, -OC1-3 alkil (gdje su zadnje dvije skupine alkilnih fragmenata opcionalno su supstituirane s jednim ili više atoma fluora); L predstavlja -C(O)N(R8)-, -N(R8)C(O)-, -S(O)2N(R8)-, - N(R8)S(O)2-, - N(R8)C(O)N(R8)-, -OC(O)N(R8)- ili -N(R8)C(O)O-; A predstavlja vodik, C1-8 alkil, C3-8 alkinil, aril, heteroaril, aril-C1-3alkil-, C3-8cikloalkil-C0-3alkil-, 4-7-člani heterocikloalkil-C0-3alkil-, heteroaril-C1-3alkil-, gdje su skupine alkil-, alkinil-, cikloalkil- i heterocikloalkil-fragmenata opcionalno supstituirane s jednim ili više supstituenata odabranih od R9a i su aril i heteroaril fragmenti opcionalno supstituirani s jednim ili više supstituenata odabranih od R9b; ili A-1- zajedno predstavljaju jednu od slijedećih skupina [image] u kojima V predstavlja vezu, -CH2CH2-, -CH2CH2CH2-, gdje u svakoj od zadnjih skupina alkilena jedna metilenska [-(CH2)-] jedinica može opcionalno biti zamijenjena s atomom kisika, , -NH- ili-N(C1-3 alkil)- skupinom i svaka metilenska jedinica može opcionalno i neovisno biti supstituirana s jednom ili dvije od slijedećih skupina: fluoro, -CN, =O, -NH2, -NH(C1-3 alkil), N(C1-3 alkil)2, -OH, -OC1-3alkil); svaki R8 neovisno predstavlja vodik, ili C1-3 alkil; svaki R9a neovisno predstavlja fluoro, -OH, -CN, =O, -NH2, -NH(C1-3 alkil), -N(C1-3 alkil)2, -OC1-6alkil, C1-6alkil, (gdje su zadnje četiri skupine fragmenata alkila opcionalno supstituirane s jednim ili više supstituenata odabranih od fluoro, -CN, =O, -NH2, -NH(C1-3 alkil), N(C1-3 alkil)2, -OH, -OC1-3 alkil) ili aril, heteroaril [gdje zadnje dvije skupine mogu biti supstituirane s jednim ili više supstituenata odabranih od halo, OH, -CN, C1-3 alkil, OC1-3 alkil (gdje su dvije zadnje alkilne skupine opcionalno supstituirane s jednim ili više atoma fluora)]; svaki R9b predstavlja neovisno halo, -OH, -CN, -NH2, -NH(C1-3 alkil), -N(C1-3 alkil)2, -OC1-3 alkil , -SC1-3 alkil, aril, heteroaril [gdje dvije zadnje skupine mogu biti supstituirane s jednim ili više supstituenata odabranih od halo, OH, -CN, C1-3 alkil, OC1-3 alkil (gdje su dvije alkilne skupine opcionalno supstituirane s jednim ili više atoma fluora)], C1-7 alkil, C2-7 alkinil, C3-7 cikloalkil, 4-7-člani heterocikloalkil (gdje su zadnje alkil, alkinil, heterocikloalkil ili cikloalkil skupine opcionalno supstituirane s jednim ili više supstituenata odabranih od fluoro, -CN, =O, -NH2, -NH(C1-3 alkil), N(C1-3 alkil)2, -OH, OC1-3alkil); njihove soli, posebice njihove fiziološki prihvatljive soli s organskim ili anorganskim kiselinama ili baza.
2. Spojevi prema zahtjevu 1, naznačeno time da su spojevi formule la [image] u kojima A, L, M, Q2, Q3, Q4, R1, R6, Ra, Rb, Rc, W, Z1, Z2, Z3 imaju isto značenje kako je definirano u zahtjevu 1, njihove soli, posebice njihove fiziološki prihvatljive soli s organskim ili anorganskim kiselinama i bazama.
3. Spojevi prema zahtjevu1, naznačeno time da su spojevi formule Ib [image] u kojima A, L, M, Q2, Q3, Q4, R1, R6, R7, Ra, Rb, Rc, W imaju isto značenje kako je definirano u zahtjevu 1, njihove soli, posebice njihove fiziološki prihvatljive soli s organskim ili anorganskim kiselinama i bazama.
4. Spojevi prema zahtjevu1, naznačeno time da su spojevi formule Ic [image] u kojima A, L, M, R1, R2, R3, R4, R6, Ra, Rb, Rc, W, Z1, Z2, Z3 imaju isto značenje kako je definirano u zahtjevu 1, njihove soli, posebice njihove fiziološki prihvatljive soli s organskim ili anorganskim kiselinama i bazama.
5. Spojevi prema zahtjevu1, naznačeno time da su spojevi formule Id [image] u kojima A, L, M, R1, R2, R3, R4, R6, R7, Ra, Rb, Rc, W imaju isto značenje kako je definirano u zahtjevu 1, njihove soli, posebice njihove fiziološki prihvatljive soli s organskim ili anorganskim kiselinama i bazama.
6. Spojevi prema bilo kojem od prethodnih zahtjeva, naznačeni time da W predstavlja -C(O)-, -S(O)2-, gdje su skupine vezane za dušik iz -NRc- dijela pomoću atoma ugljika ili sumpora; njihove soli, posebice njihove fiziološki prihvatljive soli s organskim ili anorganskim kiselinama i bazama.
7. Spojevi prema bilo kojem od prethodnih zahtjeva, naznačeni time da M predstavlja C1-7 alkil, C3-7 cikloalkil, od kojih su obje skupine opcionalno supstituirane s jednim ili više supstituenata odabranih od: fluoro, -OH, -CN, -NH2, -OC1-3 alkil, -SC1-3 alkil, aril [gdje dvije zadnje aril skupine mogu biti supstituirane s jednim ili više supstituenata odabranih od halo, OH, -CN, C1-3 alkil, OC1-3 alkil (gdje su dvije zadnje alkilne skupine opcionalno supstituirane s jednim ili više atoma fluora)], C1-7 alkil, C3-7 cikloalkil-C0-2-alkil (gdje su zadnje alkil i cikloalkil skupine opcionalno supstituirane s jednim ili više supstituenata odabranih od fluoro, -CN, =O, -NH2, -NH(C1-3 alkil), -N(C1-3 alkil)2, -OH, -OC1-3 alkil); ili aril, heteroaril, 4-7-člani heterocikloalkil, gdje su sve skupine opcionalno supstituirane s jednim ili više supstituenata odabranih od halo, -CN, -OC1-3 alkil, C1-7 alkil, C3-7 cikloalkil, (gdje su zadnje alkil i cikloalkil skupine opcionalno supstituirane s jednim ili više supstituenata odabranih od fluoro, -CN, -OC1-3alkil); njihove soli, posebice njihove fiziološki prihvatljive soli s organskim ili anorganskim kiselinama i bazama.
8. Spojevi prema bilo kojem od prethodnih zahtjeva, naznačeni time da R6 predstavlja vodik; C1-5 alkil, C3-5cikloalkil-C0-1 alkil, gdje su dvije zadnje skupine opcionalno supstituirane s jednim ili više supstituenata odabranih od fluoro, -OCH3, -NH(C1-3 alkil), N(C1-3 alkil)2; njihove soli, posebice njihove fiziološki prihvatljive soli s organskim ili anorganskim kiselinama i bazama.
9. Spojevi prema bilo kojem od prethodnih zahtjeva, naznačeni time da R2, R3 i R4 neovisno predstavljaju vodik, fluoro, kloro- ili -CH3 opcionalno supstituiran s jednim ili više atoma fluora; njihove soli, posebice njihove fiziološki prihvatljive soli s organskim ili anorganskim kiselinama i bazama.
10. Spojevi prema bilo kojem od prethodnih zahtjeva, naznačeni time da L predstavlja -C(O)NH- ili -S(O)2NH-, gdje skupine su vezane za 9-članu fuziranu heteroaromatsku građu preko odgovarajućeg atoma ugljika ili sumpora; njihove soli, posebice njihove fiziološki prihvatljive soli s organskim ili anorganskim kiselinama i bazama.
11. Spojevi prema bilo kojem od prethodnih zahtjeva, naznačeni time da svaki R7 predstavlja vodik, halo, C1-5 alkil-O-, C3-5cikloalkil-C0-2 alkil-O-, 4-5-člani heterocikloalkil-C0-2 alkil-O- (gdje su zadnje tri skupine alkil, cikloalkil ili heterocikloalkil fragmenata opcionalno supstituirane s jednim ili više supstituenata odabranih od fluoro, -OC1-3 alkil ili s jednim ili više C1-3 alkilnih skupina, koje mogu biti opcionalno supstituirane s jednim ili više atoma fluora); njihove soli, posebice njihove fiziološki prihvatljive soli s organskim ili anorganskim kiselinama i bazama.
12. Spojevi prema bilo kojem od prethodnih zahtjeva, naznačeni time da A predstavlja vodik, C1-6 alkil, C3-6 alkinil, fenil, 5-6-člani heteroaril, C3-6cikloalkil-C0-2alkil-, 4-6-člani heterocikloalkil-C0-2alkil, fenil-C1-3alkil-, 5-6-člani heteroaril-C1-3alkil gdje su skupine alkil-, alkinil-, cikloalkil- i heterocikloalkil-fragmenata opcionalno supstituirane s jednim ili više supstituenata odabranih od R9a i fenil, tienil i piridil fragmenti su opcionalno supstituirani s jednim ili dva supstituenta odabrana od R9b; svaki R9a neovisno predstavlja fluoro, fenil, C1-2alkil,-OC1-4alkil gdje su zadnje dvije skupine opcionalno supstituirane s jadnim do tri atoma fluora; svaki R9b predstavlja neovisno fluoro, chloro, bromo, C1-2 alkil, -OC1-2 alkil gdje su zadnje dvije skupine opcionalno supstituirane s jednim ili više fluoro; njihove soli, posebice njihove fiziološki prihvatljive soli s organskim ili anorganskim kiselinama i bazama.
13. Spojevi prema bilo kojem od prethodnih zahtjeva, naznačeni time da M predstavlja C1-6 alkil, C3-6 cikloalkil, 4-6-člani heterocikloalkil, od kojih su sve skupine opcionalno supstituirane s jednim ili više skupina odabranih od fluoro, -OH, -CN, -NH2, fenil, -CF3, C1-2 alkil, C3-5 cikloalkil-C0-1 alkil; ili fenil, 5-6-člani heteroaril od kojih su obje opcionalno supstituirane s jednim ili više substituenata neovisno odabranih od fluoro, kloro, metil, -CF3, -OCH3; njihove soli, posebice njihove fiziološki prihvatljive soli s organskim ili anorganskim kiselinama i bazama.
14. Spojevi prema bilo kojem od prethodnih zahtjeva, naznačeni time da su spojevi formule Ie [image] gdje A predstavlja vodik, C1-6 alkil, fenilpropargil, fenil, C3-6cikloalkil-C0-2alkil-, tetrahidrofuranil-C0-2alkil, pirolidinil-C0-2alkil, piperidin-C0-2alkil, piridil-C1-2alkil-, gdje su skupine alkil-, alkinil-, cikloalkil- i heterocikloalkil fragmenata opcionalno supstituirane s jednim ili više supstituenata odabranih od R9a i fenil i piridil fragmenti su opcionalno supstituirani s jednim ili više supstituenata odabranih od R9b; svaki R9a neovisno predstavlja fluoro, C1-2alkil, -OC1-4alkil gdje su zadnje dvije skupine alkilnih fragmenata opcionalno supstituirane s jednim ili više atoma fluora; svaki R9b predstavlja neovisno fluoro, kloro, bromo, L predstavlja -C(O)NH- ili -S(O)2NH-, gdje su skupine vezane za 9-članu fuziranu heteroaromatsku građu preko odgovarajućeg atoma ugljika ili sumpora; W predstavlja -C(O)-, -S(O)2-; M predstavlja alkil, C3-6 cikloalkil gdje su zadnje dvije skupine opcionalno supstituirane s jednim ili više skupina odabranih od fluoro, -OH, -CN, -NH2, fenil, CF3, C1-2 alkil, ciklopropil-metil; ili predstavlja oksetanil ili tetrahidrofuranil, gdje su obje skupine opcionalno supstituirane s CH3-skupinom; ili fenil, tienil od kojih su obje opcionalno supstituirane s jednom ili dva supstituenta neovisno odabrana od fluoro ili kloro, R1 predstavlja fluoro, kloro, bromo, CH3, CH2F, CHF2, CF3, -OCH3; R4 predstavlja vodik ili fluoro; R6 predstavlja vodik, C1-3 alkil, C3-5cikloalkil-C0-1 alkil, gdje su zadnje dvije skupine opcionalno supstituirane s jednim ili više supstituenata odabranih od fluoro, -OCH3, -NH(C1-3 alkil), N(C1-3 alkil)2; R7-22 predstavlja vodik, halo, -OC1-5alkil, gdje je zadnja skupina alkila opcionalno supstituirana s jednim ili više atoma fluora; R7-Z1 i R7-Z3 neovisno predstavljaju vodik ili fluoro; njihove soli, posebice njihove fiziološki prihvatljive soli s organskim ili anorganskim kiselinama i bazama.
15. Spojevi prema bilo kojem od prethodnih zahtjeva, naznačeni time da su Primjer Struktura [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] njihove soli, posebice njihove fiziološki prihvatljive soli s organskim ili anorganskim kiselinama i bazama.
16. Spojevi prema bilo kojem od prethodnih zahtjeva, naznačeni time da su za upotrebu kao farmaceutski proizvodi.
17. Farmaceutski sastav koji sadrži barem jedan spoj prema bilo kojem zahtjevu od 1 do 15 u mješavini s farmaceutski prihvatljivim pomoćnim sredstvom, razrjeđivačem ili nosačem.
18. Spojevi prema bilo kojem od zahtjeva 1 do 15, naznačeni time da su za upotrebu u prevenciji i/ili liječenju upalnih bolesti i povezanih stanja.
19. Upotreba prema zahtjevu 18, naznačena time da je stanje koje treba liječiti i/ili prevenirati bol.
HRP20150096AT 2009-03-05 2015-01-26 2-aminobenzimidazol-5-karboksamidi kao protuupalni agensi HRP20150096T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP09154414 2009-03-05
EP09179618 2009-12-17
PCT/EP2010/052799 WO2010100249A1 (en) 2009-03-05 2010-03-05 3h-imidazo [4, 5 -c] pyridine- 6 -carboxamides as anti- inflammatory agents
EP10706659.9A EP2403852B8 (en) 2009-03-05 2010-03-05 2-aminobenzimidazole-5-carboxamides as anti-inflammatory agents

Publications (1)

Publication Number Publication Date
HRP20150096T1 true HRP20150096T1 (hr) 2015-02-27

Family

ID=42111729

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20150096AT HRP20150096T1 (hr) 2009-03-05 2015-01-26 2-aminobenzimidazol-5-karboksamidi kao protuupalni agensi

Country Status (37)

Country Link
US (3) US20100256188A1 (hr)
EP (1) EP2403852B8 (hr)
JP (1) JP5433708B2 (hr)
KR (1) KR20110123764A (hr)
CN (1) CN102341395B (hr)
AP (1) AP2806A (hr)
AR (1) AR075789A1 (hr)
AU (1) AU2010220263B2 (hr)
BR (1) BRPI1009118A2 (hr)
CA (1) CA2753149A1 (hr)
CL (1) CL2011002180A1 (hr)
CO (1) CO6450668A2 (hr)
CY (1) CY1115959T1 (hr)
DK (1) DK2403852T3 (hr)
EA (1) EA020282B1 (hr)
EC (1) ECSP11011324A (hr)
ES (1) ES2528730T3 (hr)
GE (1) GEP20146034B (hr)
HK (1) HK1163064A1 (hr)
HR (1) HRP20150096T1 (hr)
IL (1) IL214033A0 (hr)
MA (1) MA33239B1 (hr)
ME (1) ME02117B (hr)
MX (1) MX2011008948A (hr)
MY (1) MY161092A (hr)
NZ (1) NZ594589A (hr)
PE (1) PE20120589A1 (hr)
PL (1) PL2403852T3 (hr)
PT (1) PT2403852E (hr)
RS (1) RS53757B1 (hr)
SG (1) SG174250A1 (hr)
SI (1) SI2403852T1 (hr)
SM (1) SMT201500053B (hr)
TN (1) TN2011000446A1 (hr)
TW (1) TWI466869B (hr)
UY (1) UY32470A (hr)
WO (1) WO2010100249A1 (hr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32138A (es) 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
US8586604B2 (en) * 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
TW201305178A (zh) 2010-10-29 2013-02-01 Glenmark Pharmaceuticals Sa 作為ｍＰＧＥＳ－１抑制物的三環化合物
US8466186B2 (en) * 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
US8486968B2 (en) * 2010-12-10 2013-07-16 Boehringer Ingelheim International Gmbh Compounds
US8674113B2 (en) * 2010-12-10 2014-03-18 Boehringer Ingelheim International Gmbh Compounds
AR084174A1 (es) 2010-12-21 2013-04-24 Lilly Co Eli Compuestos de imidazol-2-benzamida utiles para el tratamiento de osteoartritis y una composicion farmaceutica
AR086254A1 (es) 2011-05-26 2013-11-27 Lilly Co Eli Derivados de imidazol utiles para el tratamiento de artritis
WO2013038308A1 (en) 2011-09-15 2013-03-21 Glenmark Pharmaceuticals S.A. SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS mPGES-1 INHIBITORS
TWI650321B (zh) 2011-10-14 2019-02-11 美商安比特生物科學公司 雜環化合物及其使用方法
WO2013072825A1 (en) 2011-11-16 2013-05-23 Glenmark Pharmaceuticals S.A. Phtalazinone derivatives as mpegs -1 inhibitors
AR089939A1 (es) 2012-02-09 2014-10-01 Glenmark Pharmaceuticals Sa COMPUESTOS BICICLICOS COMO INHIBIDORES DE mPGES-1
US9580398B2 (en) * 2012-04-02 2017-02-28 The Trustees Of Columbia University In The City Of New York Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders
WO2013153535A1 (en) 2012-04-13 2013-10-17 Glenmark Pharmaceuticals S.A. TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
CN103450329B (zh) * 2012-05-29 2015-05-27 首都医科大学 3h-咪唑并吡啶-6-甲酰氨基酸苄酯、其合成、抗肿瘤活性和应用
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
WO2014167444A1 (en) 2013-04-08 2014-10-16 Glenmark Pharmaceuticals S.A. SUBSTITUTED BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
CA2916071A1 (en) * 2013-06-20 2014-12-24 Novasaid Ab Novel piperidinyl benzoimidazole derivatives as mpges-1 inhibitors
WO2015059618A1 (en) 2013-10-22 2015-04-30 Glenmark Pharmaceuticals S.A. SUBSTITUTED PYRIMIDINE COMPOUNDS AS mPGES-1 INHIBITORS
JP6688735B2 (ja) 2014-02-11 2020-04-28 バイエル・ファルマ・アクティエンゲゼルシャフト ｍＩＤＨ１阻害剤としてのベンズイミダゾール−２−アミン
EP3105209B1 (en) 2014-02-11 2019-08-21 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as midh1 inhibitors
CN105198960B (zh) * 2014-06-13 2018-10-19 首都医科大学 咪唑并吡啶-6-甲酰-Met-AA-OBzl,其合成,活性和应用
CN105294829B (zh) * 2014-06-13 2018-07-27 首都医科大学 咪唑并吡啶-6-甲酰-氨基酸苄酯，其合成，活性及应用
CN105198959B (zh) * 2014-06-13 2018-09-07 首都医科大学 咪唑并吡啶-6-甲酰-Met-Glu(OBzl)2,其合成,活性和应用
CN105315326A (zh) * 2014-07-10 2016-02-10 首都医科大学 咪唑并吡啶-6-甲酰-氨基酸苄酯,合成,活性和应用
CN105315335A (zh) * 2014-07-10 2016-02-10 首都医科大学 咪唑并吡啶-6-甲酰-Met-Gln-OBzl,其合成,活性和应用
CN105315325A (zh) * 2014-07-10 2016-02-10 首都医科大学 咪唑并吡啶-6-甲酰-Met-Arg(NO2)-OBzl,其合成,活性和应用
ES2723429T3 (es) 2014-08-01 2019-08-27 Glenmark Pharmaceuticals Sa Formulación de nanopartículas que comprende un inhibidor de mPGES-1
JP6783756B2 (ja) 2014-10-23 2020-11-11 ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ ｍＩＤＨ１阻害剤としてのベンゾイミダゾール−２−アミン
US10137110B2 (en) 2014-10-23 2018-11-27 Bayer Pharma Aktiengesellschaft 1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors
JO3581B1 (ar) * 2014-10-29 2020-07-05 Lilly Co Eli مركبات ميثيل-بيبيريدين جديدة مفيدة لتثبيط إنزيم سينثاز -1 بروستاجلاندين e2 ميكروسومي
AR102361A1 (es) 2014-10-29 2017-02-22 Lilly Co Eli Compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2
EP3303302B1 (en) 2015-06-08 2019-03-20 Bayer Pharma Aktiengesellschaft N-menthylbenzimidazoles as midh1 inhibitors
CN108026052B (zh) 2015-07-16 2021-10-08 德国癌症研究公共权益基金会 作为mIDH1抑制剂的5-羟烷基苯并咪唑类
GB201603311D0 (en) * 2016-02-25 2016-04-13 Jakobsson Per Johan New uses and methods
ES2963906T3 (es) 2017-11-22 2024-04-03 Khondrion Ip B V Compuestos como inhibidores de MPGES-1
CR20210687A (es) 2019-06-25 2022-03-03 Gilead Sciences Inc PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
US20230000821A1 (en) * 2019-08-26 2023-01-05 Kukje Pharma Co., Ltd. Indole carboxamide derivative and pharmaceutical composition containing same
TW202124450A (zh) 2019-10-18 2021-07-01 美商四十七股份有限公司 用於治療骨髓發育不良症候群及急性骨髓白血病之組合療法
JP2022552748A (ja) 2019-10-31 2022-12-19 フォーティ セブン， インコーポレイテッド 抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
WO2021130638A1 (en) 2019-12-24 2021-07-01 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
WO2021163064A2 (en) 2020-02-14 2021-08-19 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
KR20230006891A (ko) 2020-05-01 2023-01-11 길리애드 사이언시즈, 인코포레이티드 Cd73를 억제하는 2,4-다이옥소피리미딘 화합물
JP2023525047A (ja) 2020-05-06 2023-06-14 エイジャックス セラピューティクス， インコーポレイテッド Ｊａｋ２阻害薬としての６－ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
US20220389394A1 (en) 2021-05-18 2022-12-08 Gilead Sciences, Inc. METHODS OF USING FLT3L-Fc FUSION PROTEINS
US20220378771A1 (en) * 2021-05-25 2022-12-01 Louis Habash Modifying the expression level of a gene encoding an cyclooxygenase enzyme by treating a human subject with a nitroxide
CA3222439A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4359389A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
CA3222277A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023077030A1 (en) 2021-10-29 2023-05-04 Gilead Sciences, Inc. Cd73 compounds
TW202334139A (zh) 2021-11-09 2023-09-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳氧基苯并咪唑及氮雜苯并咪唑
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20230242508A1 (en) 2021-12-22 2023-08-03 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
US20230373950A1 (en) 2022-03-17 2023-11-23 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023183817A1 (en) 2022-03-24 2023-09-28 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345806A (zh) 2022-03-31 2023-12-01 美商艾伯維有限公司 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑
TW202345901A (zh) 2022-04-05 2023-12-01 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
US20230374036A1 (en) 2022-04-21 2023-11-23 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
WO2024137852A1 (en) 2022-12-22 2024-06-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3006671A1 (de) 1980-02-22 1981-08-27 Dr. Karl Thomae Gmbh, 7950 Biberach Neue benzoxazole, deren herstellung und deren verwendung als arzneumittel
FI91859C (fi) 1987-06-17 1994-08-25 Eisai Co Ltd Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi
JPH06759B2 (ja) 1989-09-22 1994-01-05 ファイザー製薬株式会社 新規なベンゾイミダゾール化合物
PL346248A1 (en) * 1998-08-26 2002-01-28 Aventis Pharma Ltd Aza-bicycles which modulate the inhibition of cell adhesion
DE60027700T2 (de) * 1999-02-16 2007-05-03 Aventis Pharma Ltd., West Malling Bicyclische verbindungen und ihre verwendung als integrinrezeptorliganden
IL145748A0 (en) * 1999-04-12 2002-07-25 Aventis Pharma Ltd Substituted bicyclic heteroaryl compounds as integrin antagonists
WO2000068213A1 (en) * 1999-05-05 2000-11-16 Aventis Pharma Limited Substituted bicyclic compounds
US6340681B1 (en) 1999-07-16 2002-01-22 Pfizer Inc 2-benzimidazolylamine compounds as ORL-1-receptor agonists
EP1222187B1 (en) * 1999-10-06 2004-09-22 Boehringer Ingelheim Pharmaceuticals Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
FR2833948B1 (fr) * 2001-12-21 2004-02-06 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et leur utilisation en tant que medicament
WO2003074515A1 (en) 2002-03-01 2003-09-12 Smithkline Beecham Corporation Diamino-pyrimidines and their use as angiogenesis inhibitors
IL164302A0 (en) 2002-03-29 2005-12-18 Chiron Corp Substituted benzazoles and use thereof as raf kinase inhibitors
US7037902B2 (en) 2002-07-03 2006-05-02 Receptron, Inc. Affinity small molecules for the EPO receptor
WO2004035740A2 (en) 2002-10-15 2004-04-29 Synta Pharmaceuticals Corp. Aromatic bicyclic heterocyles to modulate 1l - 12 production
WO2004072068A1 (en) 2003-02-10 2004-08-26 Amgen Inc. Vanilloid receptor ligands and their use in treatments
FR2851563B1 (fr) * 2003-02-26 2005-04-22 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
US7531553B2 (en) * 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
FR2852957B1 (fr) 2003-03-31 2005-06-10 Sod Conseils Rech Applic Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament
US7329682B2 (en) * 2003-04-03 2008-02-12 Ewha University-Industry Collaboration Foundation Method for inhibiting 5-lipoxygenase using a benzoxazole derivative
CA2543707A1 (en) 2003-10-31 2005-05-19 Takeda Pharmaceutical Company Limited Nitrogen-containing fused heterocyclic compounds
US7470712B2 (en) * 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
GB0401334D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
CA2570531A1 (en) 2004-06-18 2005-12-29 Kristofer Olofsson Indoles useful in the treatment of inflammation
US7723340B2 (en) * 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
KR20070114123A (ko) * 2005-01-19 2007-11-29 바이올리폭스 에이비 염증 치료에 유용한 인돌
JP2008531537A (ja) 2005-02-25 2008-08-14 クドス ファーマシューティカルズ リミテッド 化合物
CN102633783A (zh) * 2006-02-10 2012-08-15 转化技术制药公司 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法
WO2007124589A1 (en) 2006-05-02 2007-11-08 Merck Frosst Canada Ltd. Methods for treating or preventing neoplasias
WO2008009924A2 (en) * 2006-07-18 2008-01-24 Biolipox Ab Indoles useful in the treatment of inflammation
WO2008035956A1 (en) 2006-09-22 2008-03-27 Ewha University - Industry Collaboration Foundation New benzoxazole derivative, process for the preparation thereof and pharmaceutical composition comprising the same
EP2102177A1 (en) * 2006-12-14 2009-09-23 Boehringer Ingelheim International GmbH Benzoxazoles useful in the treatment of inflammation
WO2008129276A1 (en) 2007-04-19 2008-10-30 Boehringer Ingelheim International Gmbh Disulfonamides useful in the treatment of inflammation
UY32138A (es) 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8486968B2 (en) 2010-12-10 2013-07-16 Boehringer Ingelheim International Gmbh Compounds
US8466186B2 (en) 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
US8674113B2 (en) 2010-12-10 2014-03-18 Boehringer Ingelheim International Gmbh Compounds

Also Published As

Publication number Publication date
KR20110123764A (ko) 2011-11-15
TN2011000446A1 (en) 2013-03-27
SI2403852T1 (sl) 2015-04-30
CO6450668A2 (es) 2012-05-31
AU2010220263A1 (en) 2011-08-11
MA33239B1 (fr) 2012-05-02
SMT201500053B (it) 2015-05-05
EA201101243A1 (ru) 2012-04-30
PE20120589A1 (es) 2012-05-26
DK2403852T3 (en) 2015-01-26
US20100256188A1 (en) 2010-10-07
ES2528730T3 (es) 2015-02-12
HK1163064A1 (en) 2012-09-07
AR075789A1 (es) 2011-04-27
MX2011008948A (es) 2011-09-27
TWI466869B (zh) 2015-01-01
CN102341395B (zh) 2014-07-30
CA2753149A1 (en) 2010-09-10
EP2403852A1 (en) 2012-01-11
AP2011005807A0 (en) 2011-08-31
GEP20146034B (en) 2014-02-10
RS53757B1 (en) 2015-06-30
UY32470A (es) 2010-10-29
MY161092A (en) 2017-04-14
SG174250A1 (en) 2011-10-28
BRPI1009118A2 (pt) 2016-12-06
JP2012519205A (ja) 2012-08-23
CN102341395A (zh) 2012-02-01
CY1115959T1 (el) 2017-01-25
IL214033A0 (en) 2011-08-31
EP2403852B1 (en) 2014-10-29
TW201043604A (en) 2010-12-16
EP2403852B8 (en) 2014-12-17
US8921405B2 (en) 2014-12-30
WO2010100249A1 (en) 2010-09-10
US20120196897A1 (en) 2012-08-02
AP2806A (en) 2013-11-30
AU2010220263B2 (en) 2016-07-14
NZ594589A (en) 2014-01-31
PT2403852E (pt) 2015-02-06
US20130303571A1 (en) 2013-11-14
PL2403852T3 (pl) 2015-04-30
CL2011002180A1 (es) 2012-01-20
EA020282B1 (ru) 2014-10-30
JP5433708B2 (ja) 2014-03-05
ME02117B (me) 2015-10-20
ECSP11011324A (es) 2011-10-31

Similar Documents

Publication Publication Date Title
HRP20150096T1 (hr) 2-aminobenzimidazol-5-karboksamidi kao protuupalni agensi
HRP20200648T1 (hr) Derivati sulfamoilpirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b
HRP20160967T1 (hr) Heterociklički spojevi korisni kao pdk1 inhibitori
IL277341B2 (en) Antifibrotic pyridinones
HRP20140011T1 (hr) Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja
HRP20171040T1 (hr) Supstituirani biciklički dihidropirimidinoni i njihova uporaba za inhibiranje djelovanja elastaze neutrofila
RU2015133450A (ru) Соединения имидазопиридина и их применение
AR082443A1 (es) Formulacion de polvo seco que comprende un inhibidor de fosfodiesterasa
NZ607638A (en) Novel compounds and compositions for the inhibition of nampt
HRP20161742T1 (hr) Soli i polimorfi od 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona
HRP20130976T1 (hr) Karbonilaminopirolopirazoli, potentni inhibitori kinaza
IN2014CN03130A (hr)
RU2014141579A (ru) Гетероциклические соединения в качестве ингибиторов бета-лактамаз
AR074165A1 (es) Antagonistas de heteroalquilo de receptores de prostaglandina d2 y composiciones farmaceuticas
SI2945620T1 (en) Nitroxyl donors with improved therapeutic index
RU2015155585A (ru) 4-алкинилимидазольное производное и лекарственное средство, включающее такое производное в качестве активного ингредиента
WO2012146724A3 (en) Novel rock inhibitors
EA200970534A1 (ru) Антибактериальные производные хинолина
BR112015014433A2 (pt) compostos tricíclicos
RU2014113236A (ru) Соединения имидазопиридина, композиции и способы применения
IN2014MN02364A (hr)
JP2016535075A5 (hr)
SI2858987T1 (en) PREPARATION OF 5-PHENYL-4- (PYRIDIN-2-ILLETHYLAMINO) -CHUINAZOLIN-2-YL) -PIRIDIN-3-SULPHONAMIDE PHOSPHORAMIDIC ACID
HRP20230318T1 (hr) Derivat pirimidin sulfamida, postupak pripreme i njegova medicinska primjena
WO2015028976A3 (en) Compounds and methods for the treatment of inflammatory diseases